immatics to receive support from Pfizer for its pivotal Phase III study (IMPRINT) with IMA901
Publication date: 11 April 2011
Author: Citigate Dewe Rogerson Ltd
Tagged with: Craig Eagle, immatics biotechnologies GmbH, Paul Higham, Pfizer
immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that Pfizer has agreed to support its pivotal Phase III trial (IMPRINT = IMA901 Multi-Peptide vaccine Randomized INTernational study) with IMA901, its therapeutic cancer vaccine for advanced renal cell carcinoma.
The pivotal Phase III study will evaluate as the primary endpoint the overall survival of advanced renal cell carcinoma patients treated with IMA901 in combination with Pfizer’s Sutent® (sunitinib malate) versus Sutent® alone. The study is expected to enroll approximately 330 patients across Europe and in the US.
Pfizer will support the trial by supplying Sutent® for all the patients enrolled in the pivotal study. The first patients are expected to start treatment in April 2011.
Paul Higham, CEO of immatics, said: “We are extremely pleased that Pfizer has committed to supporting our pivotal Phase III trial with IMA901 with the supply of Sutent. Their decision reflects the growing interest in IMA901 and its potential to be an important breakthrough in the treatment of renal cell carcinoma patients.”
IMA901 has generated encouraging overall survival data, which compare favorably with historical comparisons of currently available treatments, in a Phase II trial in advanced renal cell carcinoma patients. Importantly, the Phase II study also showed an association between survival and the patient’s immune response to IMA901, as well as confirming the favorable safety profile observed in an earlier Phase I study.
“Pfizer is pleased to provide Sutent to support immatic’s clinical development program in advanced renal cell carcinoma patients,” said Craig Eagle, Vice President of Strategic Alliances and Partnerships for Pfizer Oncology. “This collaboration underscores Pfizer’s ongoing commitment to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide.”
Advertisement:
Email newsletter
If you enjoyed this article sign-up to receive our bi-weekly email newsletter:
Latest news
- Fast plasma sample cleanup with new Phree Phospholipid Removal Plates (21 May 2012)
- Two overall winners announced at prestigious national award ceremony in London’s Science Museum (18 May 2012)
- New analysis of risk stratification for TYSABRI® published in New England Journal of Medicine (18 May 2012)
- NUCYNTA® ER (tapentadol) tablets provide pain management for patients with Diabetic Peripheral Neuropathy (DPN) (18 May 2012)
- GSK statement on tender offer to acquire Human Genome Sciences (18 May 2012)
In-depth focus:
Mass Spectrometry
This free to view Mass Spectrometry in-depth focus is sponsored by Waters, Bruker, Protea and Dr. Hochmuth and contains the following articles:
- Mass spectrometry in drug discovery - Proteomics, small molecules and metablomics
- Quantification of membrane drug transporters and application in drug discovery and development
- Anthony Bristow, AstraZeneca, poses the questions for our Mass Spectrometry Leaders Roundtable
Company directory
ABB Analytical Measurements | Almac | B&W Tek, Inc. | BASF | BD Diagnostics | Bio-Optronics, Inc. | bioMérieux | BioTek Instruments, Inc. | Bruker Optics | CAMO Software AS | Catalent Pharma Solutions | Chemspec Europe Ltd | CI Precision | Cisbio Bioassays | EMD Millipore | GE Analytical Instruments | Gerresheimer Group | HACH LANGE GMBH | HORIBA Scientific | I Holland Limited | Lonza | Merck Millipore | Pall Life Sciences | Patheon Inc | Phenomenex | Porvair Sciences Ltd | Randox Pharma Services | Rapid Micro Biosystems | Realia | Roche | rommelag® | Umetrics |
Login to access exclusive content